Karlyn Dauplaise Joins Next Gen Diagnostics as Chief Commercial Officer
In an exciting development, Next Gen Diagnostics (NGD) has welcomed Karlyn Dauplaise as the new Chief Commercial Officer (CCO) of NGD Infection Prevention. This division aims to revolutionize hospital practices surrounding the detection and prevention of infections. Karlyn's remarkable expertise in healthcare strategy positions her as a key player in this initiative, ensuring that hospitals can more effectively manage infection risks.
The Role of CCO in NGD
As CCO, Karlyn will spearhead commercial strategy, cultivate market development opportunities, and establish strong customer partnerships to promote the adoption of NGD’s innovative real-time transmission detection solutions. Her vision will be essential in guiding integrated delivery networks (IDNs) to implement advanced genomic surveillance systems. These systems are designed to minimize preventable harm, enhance patient safety, and improve overall operational efficiency.
Experience and Expertise of Karlyn Dauplaise
Karlyn joins NGD with a wealth of experience from her previous senior role at Vizient, the foremost healthcare performance improvement organization in the nation. At Vizient, she collaborated with hospital executives nationwide, championing quality improvements and optimizing both clinical and operational processes. Her reputation for advancing value-based care strategies and adopting pioneering technologies further strengthens her capability to lead at NGD.
Strategic Vision for Infection Prevention
Dr. Paul A. Rhodes, the Founder and CEO of Next Gen Diagnostics, expressed his enthusiasm about Karlyn’s appointment. He highlighted her profound understanding of health systems and her talent for making complex innovations practical. Karlyn’s extensive industry networks will undoubtedly assist hospitals as they increasingly rely on cutting-edge genomic surveillance solutions to prevent the spread of infections.
Expressing her excitement, Karlyn Dauplaise remarked on the critical timing of joining NGD Infection Prevention. She emphasized the urgent need for practical, high-impact tools that can significantly reduce harm in hospitals. Karlyn believes NGD's real-time whole-genome sequencing (WGS) platform provides a transformative chance for health systems to detect infections earlier, respond swiftly, and ultimately enhance patient outcomes.
Overview of NGD Infection Prevention
NGD Infection Prevention is at the forefront of healthcare innovation with its automated whole-genome sequencing technology. This cutting-edge approach to infection management helps hospitals significantly reduce preventable infections while also enhancing patient safety and streamlining operational performance. The unique NGD200 system processes multiple samples simultaneously, minimizing hands-on time and offering integrated bioinformatics, which ensures actionable insights at an economical cost per sample. This capability provides the potential for widespread adoption across different healthcare settings.
Company Vision and Advancements
Next Gen Diagnostics (NGD) embodies the future of biotechnology, focusing on the development of advanced genomic solutions for healthcare challenges. Beyond NGD Infection Prevention, the company is pioneering predictive models that evaluate antimicrobial resistance. This innovation leads to more accurate antibiotic decision-making and invariably supports the development of new antibiotic alternatives. With a base in the U.S. and additional laboratories in various global locations, NGD continues to push the boundaries of medical science.
Frequently Asked Questions
Who is Karlyn Dauplaise?
Karlyn Dauplaise is the new Chief Commercial Officer at Next Gen Diagnostics, specializing in healthcare strategy.
What is NGD Infection Prevention?
NGD Infection Prevention is a division of Next Gen Diagnostics focusing on infection detection and prevention using genomic technologies.
What technologies does NGD use?
NGD employs automated whole-genome sequencing and real-time transmission detection to aid hospitals.
Where is Next Gen Diagnostics headquartered?
Next Gen Diagnostics is based in the U.S., with a lab in Cambridge, Massachusetts, and offices in Boston and Cambridge, UK.
What experience does Karlyn bring to NGD?
Karlyn has extensive experience in healthcare performance improvement from her work at Vizient, enhancing hospital outcomes.
